hypertensive disorders of pregnancy
BP ≥140/90 in pregnancy = treat (SOGC 2022), target DBP 85. ≥160/110 = emergency — treat within 60 min to prevent stroke. Preeclampsia = new/worsening HTN + proteinuria or any adverse condition — proteinuria not required. MgSO₄ is seizure prophylaxis, not an antihypertensive. Delivery is definitive but BP peaks day 3–6 postpartum. Aspirin + exercise prevent it.
acute severe hypertension (≥160/110)
Confirm (repeat in 15 min) → treat within 60 min, antepartum or postpartum. Severe systolic alone suffices. Target: out of severe range, then DBP ~85; avoid precipitous drops (uteroplacental perfusion). If already on a daily agent, use a drug from a different class.
| drug | T0 | then | max / caution |
|---|---|---|---|
| nifedipine capsule PO | 5–10 mg | 10 mg q30–60 min (at 30, 90, 150 min) | swallow whole — don’t bite or puncture; headache, tachycardia |
| labetalol IV bolus | 10–20 mg | 20–40 mg at 30 min, then 40–80 mg q30 min | max 300 mg per course; avoid uncontrolled asthma, HF |
| labetalol IV infusion | 0.5–2 mg/min | titrate | neonatal bradycardia/hypoglycaemia → newborn glucose screen |
| labetalol PO | 200 mg | 200 mg q1h × 2 more | contraindicated in uncontrolled asthma, HF |
| hydralazine IV | 5 mg | 5–10 mg q30 min | max 20 mg; hypotension, maternal/foetal tachycardia |
| methyldopa PO | 1000 mg | — | slow onset; often needs a second agent |
- Reassess 30 min after IV agents or nifedipine; 60 min after other oral agents
- Uncontrolled after ~3 h → switch class (after nifedipine/hydralazine → oral labetalol or methyldopa)
- Once controlled → routine oral maintenance (chronic hypertension in pregnancy)
- Severe BP = MgSO₄ indication — give both (magnesium sulfate); Mg isn’t an antihypertensive
- Pulmonary oedema → hydralazine/nitrate ± furosemide, not labetalol
- Labour fluids ~80 mL/h total (↓ pulmonary oedema, no ↑ AKI); oliguria → assess volume, don’t reflexively bolus
- Admit if severe HTN or any adverse condition; no bed rest
XL is maintenance; the immediate-release capsule (swallowed whole) is the acute agent. Formulation errors are common.
classification and diagnosis
| type | definition |
|---|---|
| pre-existing (chronic) | before pregnancy or <20 wk — see chronic hypertension in pregnancy |
| gestational | new ≥20 wk, no adverse conditions |
| preeclampsia | new/worsening HTN + ≥1 of: proteinuria, adverse condition, severe complication |
| superimposed preeclampsia | preeclampsia on chronic HTN |
- HTN: office ≥140/90 (average of ≥2 readings, 15 min apart); ABPM/home ≥135/85
- Proteinuria: uPCR ≥30 mg/mmol, uACR ≥8 mg/mmol, ≥0.3 g/24 h, or ≥2+ dipstick (dipstick = screen only)
- HELLP and eclampsia can occur with normal BP or before proteinuria
- Uric acid: not a diagnostic test; sFlt-1:PlGF / PlGF where available (assay-specific)
SOGC adverse conditions vs severe complications
| system | adverse condition → monitor, plan delivery | severe complication → deliver regardless of GA + MgSO₄ |
|---|---|---|
| CNS | severe headache, visual symptoms | eclampsia, PRES, cortical blindness or retinal detachment, GCS <13, stroke/TIA/RIND |
| cardiorespiratory | chest pain, dyspnoea, SpO₂ <97% | uncontrolled severe HTN >12 h on 3 agents, SpO₂ <90%, pulmonary oedema, inotropes, MI |
| haematological | low platelets | plt <50, transfusion of any blood product |
| renal | rising Cr | AKI (Cr >150 µmol/L, no prior CKD), new dialysis indication |
| hepatic | RUQ/epigastric pain, ↑AST/ALT | INR >2 without DIC/warfarin, hepatic haematoma/rupture |
| uteroplacental | FGR, oligohydramnios, absent/reversed umbilical EDF, abnormal NST/CTG, angiogenic imbalance (e.g. sFlt-1:PlGF >85) | abruption with maternal/foetal compromise, reversed ductus venosus a-wave, foetal death |
Workup: SpO₂, plt, Cr, AST/ALT (SOGC minimum) + film, LDH, bilirubin, uPCR; INR/fibrinogen if plt low or severe. Repeat at least twice weekly. Trends > single values. Once proteinuria criteria are met, don’t repeat it.
delivery
Placenta out = definitive. Decision with obstetrics; involve anaesthesia, paediatrics.
| scenario | timing |
|---|---|
| severe complication (table above) or foetal compromise | deliver now, regardless of GA |
| preeclampsia <34 wk | expectant only in a centre able to care for very preterm infants |
| preeclampsia 34⁺⁰–35⁺⁶ wk | discuss delivery (↓ maternal, ↑ neonatal risk) |
| preeclampsia 36⁺⁰–36⁺⁶ wk | consider delivery |
| preeclampsia ≥37 wk | deliver |
| gestational / chronic HTN, no preeclampsia | offer at 38⁺⁰–39⁺⁶ wk; advise from 40⁺⁰ wk |
- Betamethasone 12 mg IM q24h × 2 if ≤34⁺⁶ wk and delivery likely within 7 d — don’t delay indicated delivery to complete it
- Steroids to treat HELLP: not recommended (transient lab improvement, no outcome benefit)
- Platelet transfusion: <20 before vaginal, <50 before caesarean, or any time with active bleeding/rapid fall/coagulopathy
- Preeclampsia ≠ indication for caesarean
- Neuraxial: plt ≥75 typically acceptable without coagulopathy (anaesthesia-specific) — see haematology in pregnancy
postpartum
- BP peaks day 3–7 (vasoconstriction returns, angiogenic factors persist); up to ~25% have postpartum HTN
- Eclampsia, stroke, and de novo preeclampsia occur after discharge — mostly within 2 wk
- BP at least twice in the first 2 wk (ACOG: by day 3–10); home BP monitoring
- New/worsening HTN or symptoms postpartum → full preeclampsia workup
- Breastfeeding (SOGC): labetalol, methyldopa, nifedipine, enalapril, captopril (ACEi fine postpartum)
- Severe postpartum BP → same acute treatment + MgSO₄ if neuro symptoms
Retained placental tissue can sustain the angiogenic imbalance → persistent/worsening preeclampsia, HELLP, or late eclampsia. Pelvic US ± obstetric review; evacuation if RPOC present. Evidence = case series, but cheap to exclude.
prevention
| intervention | who | detail (SOGC 2022) |
|---|---|---|
| exercise | all (strong recommendation) | ≥140 min/wk moderate intensity → ~25% ↓ gestational HTN and preeclampsia |
| aspirin 81 or 162 mg qhs | ≥1 high-risk or ≥2 moderate-risk factors | before 16 wk, stop by 36 wk; SOGC: 81 or 162 mg, individualise — consider >81 mg; not for others |
| calcium | dietary intake <900 mg/d | ≥500 mg/d supplement |
| diet + exercise | overweight/obese at increased risk | ↓ calories, low glycaemic index |
| vitamin D above standard dose | — | not recommended |
- High risk (any 1): prior preeclampsia, BMI >30, chronic HTN, pregestational DM, CKD, SLE/APS, ART
- Moderate risk (≥2): nulliparity, multifetal pregnancy, age >40, prior abruption, stillbirth, or FGR
- Where available: 11–14 wk screening combining clinical factors + uterine artery PI + PlGF (FMF model)
- GDM alone ≠ aspirin indication
- Treat OSA (CPAP) and optimise BP/glycaemia/CKD pre-conception
- Aspirin after placental disease is established doesn’t reverse it — timing matters
SOGC: at least 140 min/wk of moderate-intensity activity (raises HR; can talk, can’t sing — brisk walking, water aerobics, stationary cycling, resistance training, gardening) → ~25% lower odds of gestational HTN and preeclampsia (also ↓ GDM). Canadian physical activity guideline: 150 min/wk over ≥3 days. Absolute contraindications include placenta praevia after 28 wk, preeclampsia, uncontrolled HTN, ruptured membranes, preterm labour.
long-term cardiovascular risk
- Lifelong risk enhancer: ~4× chronic HTN, ~2× IHD and stroke (Bellamy, BMJ. 2007); ↑ HF, T2DM, CKD — highest after early-onset/severe preeclampsia
- Recurrence ~1 in 6; ~25% if prior onset <34 wk, ~50% if <28 wk → aspirin from 12–16 wk next time
- BP/labs normalise by 6 wk–3 months (up to 12); HTN persisting >6–12 months → secondary HTN workup
- 6-wk visit: counsel on recurrence and CV risk; screen BP, lipids, glucose, weight; avoid interpregnancy weight gain
- No statin while breastfeeding — lipids inform later risk
Record HDP as a diagnosis in the discharge summary — postpartum attendance alone doesn’t trigger CV prevention.
evidence
- CHIPS (2015) — tight (DBP 85) vs less-tight (DBP 100): no difference in perinatal outcome; less-tight → more severe maternal HTN (41% vs 28%)
- ASPRE (2017) — aspirin 150 mg qhs from 11–14 wk in screen-positive singletons: preterm preeclampsia 1.6% vs 4.3%
- Davenport, Br J Sports Med. 2018 — exercise: gestational HTN OR 0.61, preeclampsia OR 0.59
Prepared 2026-10-15. Not yet verified — check every number against the sources.